Poseida Therapeutics Inc., of San Diego, reported that P-BCMA-101, its B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T-cell (CAR T) candidate for the treatment of multiple myeloma, typically reduced tumor burden to the limit of detection within six to nine days in what it called "an ultra-stringent" p53 knockout mouse xenograft model.